Stock Price & Analysis

Based on the provided data, I'll analyze whether to buy or sell NVS stock.

Technical Analysis The stock is currently trading at $97.53, showing a slight decline of -0.34% in the regular market session. The RSI(14) at 38.67 indicates the stock is approaching oversold territory but hasn't reached extreme levels yet. The MACD at -0.80 suggests bearish momentum in the near term.

Recent Developments A significant positive development is that the US Court of Appeals has upheld Novartis's Entresto patent and temporarily blocked generic competition. This is crucial as Entresto was Novartis's top-selling drug in 2023 with $6 billion in sales, and this legal victory helps protect this revenue stream through July 2025.

Recommendation Given the patent protection for Entresto through mid-2025 and current technical indicators showing oversold conditions, NVS presents a buying opportunity at current levels.

Based on the provided data and context, here's my analysis for NVS stock price prediction in 2025:

Price Target Analysis:

Novartis (NVS) is expected to reach $102-103 by mid-2025, driven by three key factors:

1. The successful defense of Entresto patent through July 2025, which will protect this $6 billion revenue stream from generic competition.

2. Strong performance from oncology, immunology and neuroscience medicines showing 20% growth in non-incretin revenue.

3. Technical indicators showing Fibonacci resistance levels at $101-102.3, suggesting this as a realistic target range.

Technical Support: The stock currently trades around $97.53 with strong Fibonacci support at $96.68 and $95.35, providing a solid foundation for upward movement. The RSI at 38.67 indicates the stock is approaching oversold territory, suggesting potential for upward price correction.

The S1 support level for NVS Stock is $97.79 ,The R1 resistant level for NVS Stock is $99.93.

As of the end of day on 2025-01-24, the price of NVS Stock was $99.97.

The target price for NVS Stock according to analyst rating is 140.50, with the highest price target at 156.00 and the lowest at 125.00. Analysts have a Moderate Buy rating on NVS Stock overall.

The market cap of NVS is $199.9B.

Based on the provided financial data and recent analyst ratings, here's a concise analysis of whether NVS is overvalued:

Valuation Analysis: NVS's Q3 2024 PE ratio of 20.83 is reasonable for a pharmaceutical company, showing a declining trend from 22.04 in Q1 2024, suggesting improving valuation metrics.

Growth & Profitability: The company demonstrates solid financial health with increasing quarterly revenue from $12.12B to $13.17B in Q3 2024, alongside improving ROE from 19.86% to 28.87%.

Analyst Consensus: Recent analyst actions show a shift from "Strong Buy" to "Hold" ratings, with multiple downgrades in late 2024, including from Goldman Sachs, B of A Securities, and Jefferies, suggesting the stock may be fairly valued at current levels.

Market Position: The company maintains strong margins with gross margin at 75.39% and net margin at 24.18% in Q3 2024, indicating robust operational efficiency.

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Based on the provided data, here is a comprehensive analysis of NVS stock price prediction for 2030:

Novartis (NVS) stock is projected to reach $175-180 by 2030, driven by its strong pipeline in oncology and continued dominance in cardiovascular medications like Entresto. The recent federal court ruling upholding Entresto's patent through July 2025 provides near-term revenue stability, as it was Novartis's top-selling drug generating $6 billion in sales in 2023.

The company's strategic focus on expanding its presence in key therapeutic areas and investment in next-generation treatments positions it well for sustainable long-term growth through 2030.

NVS has a total of 76057 employees.